Elexacaftor, tezacaftor, and ivacaftor and Repaglinide interaction
Elexacaftor, tezacaftor, and ivacaftor and Repaglinide: the Elexacaftor, tezacaftor, and ivacaftor prescribing label describes an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Elexacaftor, tezacaftor, and ivacaftor (Trikafta) label · effective 2026-06-22
Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.